The reason is the emergence of secondary resistant mutations showing highly heterogeneous, and these TKIs are active against only a subset of the KIT secondary mutational spectrum, which constitutes the main determinant for treatment failure in imatinib-resistant GIST. This evidence concerns the gene KIT and gastrointestinal stromal tumor.